Neurocrine Biosciences | NBIX - Capital Ordinário





Capital Ordinário Alterar Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amgen USD 539M 1000K 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Cytokinetics USD 122.26M 145K 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Exelixis USD 268.1M 2.03M 2025-09
Gilead Sciences USD 1.24B 1000K 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Incyte USD 198.46M 2.33M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Pfizer USD 5.69B 1000K 2025-09
Prothena USD 53.83M 3K 2025-12
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Repligen USD 56.32M 42K 2025-12
Rigel Pharmaceuticals USD 17K 158K 2024-06
Sarepta Therapeutics USD 104.96M 196K 2025-12
Teva Pharmaceutical Industries USD 1.15B 0 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12
Xoma USD 87K 1000 2024-06